EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM
See full prescribing information for complete boxed warning.
- TRADE NAME: Pomalyst (Celgene)
- INDICATIONS: Multiple myeloma in patients who have received at least two prior therapies including lenalidomide and bortezomib
- CLASS: Immunomodulator, Thalidomide analog
- HALF-LIFE: 7.5–9.5 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Ketoconazole, P-glycoprotein, Rifampin
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of pomalidomide in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
